News

When Hope Lancaster Colquhoun was prescribed Mounjaro and instantly shed the pounds, the jab felt like a 'lifeline'. But her ...
Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily ...
As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...
Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...
Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...
The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 ...
Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...
Vivienne Joy runs a community of hundreds of weight loss jab users and said the increased cost of Mounjaro had 'created chaos ...
COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...